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Human  polymorphonuclear  leukocytes  (PMN) 1 metabolize  arachidonic  acid  via 
the lipoxygenase pathway to a number of mono- and di-hydroxyeicosatetraenoic acids 
(HETE)  (1-7).  These  HETE  include  5-D-HETE,  12-L-HETE,  12-L-hydroperoxy- 
ETE, and at least four isomers of 5,12-diHETE. In addition to arachidonic acid, these 
HETE have been shown to induce chemotaxis (8-11), chemokinesis (12,  13), degran- 
ulation  (14-17),  and aggregation  (13,  15,  18)  of human PMN  in vitro.  The potency 
of these  metabolites  to  induce  chemokinesis  is  dependent  on  the  position  of the 
substituted  hydroxyl groups  (5,12-diHETE  >  5-HETE  >  12-HETE  >  12-HPETE 
>  arachidonic acid [12,  19]). Methyl-ester derivatives of 12-HETE specifically inhibit 
the chemotactic response to the parent  molecule (19, 20). Among the four isomers of 
5,12-diHETE, 5S, 12R-dihydroxy-6(cis),8 ( trans ) , 10 ( trans ), 14 ( cis )-E TE  (leukotriene B4 
[LTB,]) is the most active in inducing chemokinesis of human neutrophils, aggregation 
of rat  PMN,  and  changes  in  vascular  permeability  in  vivo  (21).  LTB4  produces 
cellular  responses  in  vitro  at  nanomolar  concentrations  and  is  several  times  more 
active  than  the  stereoisomers  5S,12R-dihydroxy-6,8,10(all  trans)14(cis)-ETE  and 
5S, 12S-6,8,10 (all  tram), 14(cis)-ETE  (6-trans-LTB4  and  12-epi-6-trans  LTB4,  respec- 
tively)  (3,  21). This difference in potency of LTB, from its diastereoisomers  suggests 
the existence of highly specific receptor(s)  which are directly involved in modulating 
PMN responses  (21).  In this  report, we describe the binding of [aH]LTB4 to human 
PMN. The binding is shown to he saturable and specific, consistent with the existence 
of a  specific receptor for LTB4. The metabolism of LTB4 on incubation with human 
PMN is also described. 
Materials  and Methods 
Sources of Materials.  Arachidonic acid (Nu Check Prep, Inc., Elysian, MN; N-[pahenylalanine- 
ring-2,6,3H(N)]-formyl-methionyl-leucyl-phenylalanine  (47  Ci/mmol),  [3-20-HI  N-arachi- 
donic acid  (240  Ci/mmol),  a  generous gift  of New  England  Nuclear,  Boston, MA;  [1-14C]- 
arachidonic  acid  (55  mCi/mmol)  (Amersham,  Arlington  Heights,  IL);  A23187,  lipid-poor 
* Supported by grant  5 T  32 GMO 7200 from the  Medical Scientist Training  Program,  National 
Institute of General Medical Sciences. 
1Abbreviations used in this paper: ETE, 6,8,10,14-eicosatetraenoic acid; HETE,  monohydroxy-ETE; di- 
HETE,  dihydroxy-ETE; 5-HPETE,  5-bydroperoxy-ETE; LTB4, 5S,12R-dihydroxy-6(cis),8,10(trans),14- 
(cis)-ETE;  6-trans-LTB,,  5S,12R-dihydroxy-6,8,10,(all trans),  14(cis)-ETE;  12-epi-6-trans-LTB4, 5S, 12S- 
dihydroxy-6,8,10(all trans), 14(cz))-ETE; 5S, 12S-DHETE,  5S, 12S-dihydroxy-6(trans),8(cis),  10(trans), 14(ct))- 
ETE; FMLP, N-formyl-methionyl-leucyl-phenylalanine;  ICs0, inhibitor concentration giving 50% inhibi- 
tion; PMN, polymorphonuclear leukocyte; RP-HPLC, reverse phase high pressure liquid chromatography; 
SP-HPLC, straight phase high pressure liquid chromatography; TLC, thin-layer chromatography. 
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bovine serum albumin (Calbiochem-Behring  Corp., La Jolla, CA); Hepes, N-formyl-methionyl- 
leueyl-phenylalanine  (FMLP) (Sigma Chemical Co., St. Louis, MO); Ficoll-Paque, Pharmacia 
Fine Chemicals, Inc., Piscataway, NJ. 
Purification of Cells.  Purified  human PMN  were  prepared  from  heparinized peripheral 
venous blood by dextran sedimentation of erythrocytes followed  by isopycnic centrifugation 
using a Ficoll-Hypaque gradient (22). Residual contaminating erythrocytes were removed by 
hypotonie lysis. Platelets were removed by repeated low speed centrifugation to levels of less 
than one platelet per nucleated cell.  More  than 98%  of the  nucleated cells  were  PMN as 
determined  morphologically  (Wrights  stain).  Human  peripheral  blood  lymphocytes  were 
prepared by the procedure described previously (23). Approximately 95% of the nucleated cells 
were lymphocytes. Contamination  of platelets and erythrocytes was minimal (usually less than 
one platelet or erythrocyte per nucleated cell). Cells were examined for viability by exclusion 
of supervital dye (24). Viability was routinely >95%. 
Preparation of [aH]-  and  [t4C]5,12-diHETE.  Radiolabeled 5,12-diHETE  (LTB4,  6-trans- 
LTB4,  and  12-epi-6-trans-LTB4)  were  prepared  by  incubation of  human  PMN  with  the 
ionophore A23187 in the presence of radiolabeled arachidonic acid as described elsewhere  (25, 
26). In brief, PMN at a concentration of 1 ×  l0  s cells/ml in Dulbecco's phosphate-buffered 
saline (27), pH 7.4, were incubated with 10 pg/ml A23187 and either 4.8 #g/ml [ H]arachidonie 
acid diluted 1:3 with cold arachidonate or 38.3 pg/ml arachidonic acid containing a  tracer 
amount of [14C]arachidonic  acid. The cells were incubated with the [3H]ligand for 5 min at 
37°C in a final volume of 2 ml. The cells were then added to 3.75 ml of methanol and agitated 
vigorously.  The extraction mixture was centrifuged at  1,200 rpm for 10 rain at 4°C, and the 
supernatant was removed. The pellet was washed with an additional 1.25 ml of methanol and 
recentrifuged. The supernatants were combined, acidified to an apparent pH of 3, and added 
to a mixture of 15 ml peroxide-free ether and 10 ml water. After vigorous mixing, the water 
phase was removed and the ether phase was washed with an additional 2.5 ml water. The ether 
phase was  dried under N2.  The residue was  dissolved in a  small volume of methanol and 
applied to  a  17  ×  1.2-cm  column of silicie  acid  (silicic acid,  100 mesh,  Mallinekrodt Inc., 
Science Products Div., St. Louis, MO) (heated at 110°C just before use, packed in chloroform/ 
methanol 7:3, vol/vol). The 5,12-diHETE eluted in the first fraction with chloroform/methanol, 
7:3 (vol/vol). This fraction was dried under N2 and chromatographed on silica gel G-coated 
plates  (Brinkman Instruments, Inc., Westbury, NY)  developed with benzene/diethyl ether/ 
ethanol/acetic acid (50:40:2.0:0.2,  vol/vol/vol/vol) (1). The thin-layer chromatography (TLC) 
plates were autoradiographed, and the 5-HETE and 5,12-diHETE bands were identified by 
comparison with radiolabeled reference standards prepared and characterized by Dr. William 
Stenson (Dept. of Medicine, Washington University) or ourselves  using previously described 
methods (1, 5, 28, 29), including  in some instances mass spectroscopy.  The bands were scraped, 
eluted in methanol, and further analyzed and purified by high pressure liquid chromatography. 
Reverse-phase high pressure liquid chromatography (RP-HPLC) was performed on a Varian 
model 8550 instrument (Varian Associates,  Palo Alto, CA) using a #Bondapack C-18 column 
(4 ×  250 mm) (Waters Associates, Milford, MA) in a solvent system of methanol/water/acetic 
acid, 700:300:01 (vol/vol/vol), at 25°C and a flow rate of 1 ml/min. Three of the 5,12-diHETE 
isomers used in this paper (Table I) gave single peaks on HPLC (UV monitor, 280 nm) that 
were clearly separated from one another. In this system, 6-trans-LTB4,  12-epi-6-trans-LTB4,  and 
TABLE  I 
Identification of 14 C-5,12-diHETE* 
Ultraviolet  Retention  time 
rf~  maxima  HPLC 
minutes 
6-trans-LTB4,  5S, 12R-dihydroxy-6,8,10(all tram) 14~is-ETE  0.21  258, 268, 279  12 
12-epi-6-trans-LTB4  5S,12S-dihydroxy-6,S,10(all trans)14cis-ETE  0.19  258, 268, 279  13.2 
LTB4  5S,12R-dihydroxy-6cis,8,1Otrans,14cis-ETE  0.17  260, 270, 280  14.5 
5S,12S-diHETE  5S,12S-dihydroxy-6,1Otrans,8,14cis-ETE  0A6  258, 268, 278  -- 
* See Methods and Materials for synthesis and isolation procedures. 
:~ Fractional distance migrated as compared with solvent front on TLC. 630  LEUKOTRIENE  B4  RECEPTOR 
LTB4  eluted  at  12,  13.2,  and  14.5  min,  respectively. In  addition,  the  LTB4  fraction  was 
examined for the presence of 5S,12S-dihydroxy-6(trans),8(cis),lO(trans)14(cis)-ETE  (5S,12S- 
diHETE)  as described by Borgeat et al.  (30).  A  sample of LTB4 was methylated by reaction 
with diazomethane, and the products were evaluated by both reverse-phase and straight-phase 
(SP)  HPLC  (Fig.  1).  On RP-HPLC  ~uBondapack C18 column, methanol/water/acetic acid, 
75/25/0.1, pH 5.4, flow at  1 ml/min) the derivitized fraction gave a single peak at  15 min. SP- 
HPLC was performed in an isocratic system of hexane/isopropanol/acetic acid, 94/6/0.1  on a 
/~Porasil column (Waters Associates) with a  flow rate of 1 ml/min. In this system, the LTB4- 
methyl ester was obtained at  19.0  rain with minor peaks at  10  and  14  min  (Fig. 2).  Greater 
than 95% of the [SH]LTB4  counts were associated with the 19-min peak. Fewer than 5% of the 
counts occurred in the 10-min peak which corresponds to the 5S,12S-DHETE isomer (30).  The 
[14C]LTB4  preparation,  however,  was  found  to  contain  ~10-15%  of the  isomer as  counts 
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FIG.  1.  Reverse-phase and straight-phase HPLC chromatograms of the methyl ester of [14C]LTB4. 
Methyl esters of the LTB4 fraction  seen in the top panel of Fig.  1 were formed on reaction with 
diazomethane at 25°C and then separated on either reverse-phase  (top) or straight-phase (bottom) 
HPLC. The reverse-phase HPLC was run on a #Bondapack Cls column at 1 ml/min in methanol/ 
water/acetic acid 75:25:0.1. The methyl ester of LTB4 eluted at  15 min, with unmethylated LTB4 
eluting at 9 rain. The methyl-ester eluted at  19 min on a straight-phase column (#Porasil; Waters 
Associates) in hexane/isopropanol, 94/6, 0.1% acetic  acid.  A second, minor peak is seen at  10-11 
min, which corresponds to the 12-epi-6-trans-8-cis-LTB4  isomer. R.  A.  KREISLE AND CHARLES W.  PARKER  631 
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FIo.  2.  Time course  of [aH]LTB4 binding to human  neutrophils at  4°C and  37°C. Cells  were 
incubated at a concentration of 1.5 ×  107 cells/ml with 8 nM [at~I]LTB~ at 37°C (0) or 4°C (ff]). 
After incubation for the indicated time a  I00-#! aliquot (1.5 ×  10  ~ cells) was centrifuged through a 
30% Ficoll-Paque gradient. The cell pellet was then processed for radioactivity and protein content 
as described  in Materials and Methods. (B) Linearity of [3H]LTB4 binding with cell concentration. 
Human PMN were incubated at varying concentrations with 4 nM [3H]LTB4 for 45 min at 4°C. At 
the end of the incubation,  a  100-pl aliquot of cell suspension  was  processed  as in A. All points 
represent  the mean of triplicate samples  +  SD. 
recovered in  the  10-min  peak.  Thus,  the  [3H]ligand  was  essentially pure,  whereas  the  [14C]- 
ligand contained a small, but significant amount of the 5S, 12S-DHETE isomer. The presence 
of this isomer and  its possible effects on the ability of the ['4C]LTB, to block the binding of 
[3H]LTB4  are  discussed  below.  The  5S,12S-DHETE  was  prepared  by  scraping  the  band 
immediately below the LTB4, eluting with methanol,  and  then reapplying to the same TLC 
system  with  multiple  consecutive  runs  of solvent.  This  procedure  served  to  maximize  the 
separation of the LTB4 and 5S,12S-DHETE isomer and allow recovery of either isomer in the 
form of the free acids, avoiding the necessity of saponifying the material.  Further characteri- 
zation of the 5S,12S-DHETE band showed maxima of the ultraviolet spectrum to be 258, 268, 
278 (R. A. Kreisle and C. W. Parker, manuscript  in preparation). 
Estimates  of total  recovery and  specific activity of the LTB4 as calculated  in the original 
incubation mixture and spectrophotometric measurements at 270 nm with a  molar extinction 
coefficient of 47,000  (4)  were  in  good  agreement.  Synthesis  and  isolation  of [14C]LTB4  was 
3  carried out in a  manner identical to the [ H]LTB4, except that  the ether extracts were plated 
directly  on  thin-layer  chromatography  plates  without  separation  on  a  silicic acid  column. 
Products of both the [3Hi- and  [14C]arachidonic acid incubations appeared  to be identical by 
TLC,  HPLC,  and  ultraviolet  spectra.  The  radiolabeled  ligands  were  stored  at  -20°C  in 
methanol or chloroform and remained homogeneous to TLC for up to 6 too. 
Chemokinesis Assay.  The chemokinetic activity of [3H]LTB4 and  [a*C]LTB, was assayed by 
the agarose microdroplet assay of Smith and Walker (13,  31) in Gey's medium (32). 
Binding Assay.  PMN were incubated  in triplicate at a  concentration of 1 ×  107 cells/ml in 
Gey's medium (23) with 25 mM Hepes, pH 7.4 and varying amounts of [ZH]LTB4 and blockers 
at 4°C. Incubations were started by addition of [3H]LTB4 (final concentration 8 nM) with the 
blocking agent  (various concentrations)  or buffer,  using a  final incubation  volume of 130 #1. 
Cells were routinely incubated for 45 rain at 4°C (except as noted). At the end of the incubation, 
100/~1 of the incubation mixture was layered on top of a  200-pl layer of 30% Ficoll-Hypaque in 
buffer in  a  400-/~1 polyethylene microtest  tube  (Bio-Rad Laboratories,  Richmond,  CA).  The 
cells were pelleted by centrifugation for 2 rain in a  Beckman model  152  microfuge (Beckman 
Instruments, Fullerton, CA). This method allowed for the rapid separation of the cells from the 
incubation mixture with minimal contamination  by free ligand (<2% in the 50 #1 of gradient 
immediately above the pellet area in control experiment without cells). The supernatant  and 
gradient  were removed by aspiration,  and  the bottom  of the tube containing the pellet was 
excised (33). The pellet was solubilized in 0.5 ml  1 N  NaOH at 50°C for 2 h. The solubilized 
pellet was neutralized with 0.5 ml 1 N  HCI, and  100/LI was processed for protein measurements 
as  described  below.  The  remaining  900 pl  was  counted  for  10  rain  or longer in  Scintiverse 632  LEUKOTRIENE B4  RECEPTOR 
(Fisher Scientific Co., Pittsburgh,  PA) on a Beckman model LS8100 scintillation  counter and 
the data were corrected for background and crossover between the 3H and t4C channels. 
Recovery of cells in the pellet was monitored by protein  determinations  (34) of a fraction of 
the solubilized pellets. The amount of protein was found to be linearly related  to the number 
of cells layered on top of the 30% Ficoll-Hypaque  gradient.  For both PMN and lymphocytes, 
recovery of protein  from cells pelleted  through the gradient  was >95% of that  for an equal 
number of cells pelleted through buffer alone. Apparently complete recovery of cells occurred 
under all of the conditions tested including  the highest concentrations  of [I4C]5,12-diHETE. 
All conditions were carried out in triplicate  and major experimental  conclusions were verified 
on multiple occasions. 
Results 
Characterization of[3H]LTB4 and [14C]LTB4.  To screen for the possible presence of 
high affinity receptors on human PMN for LTB4, [3H]LTB4 of high specific activity 
was prepared biosynthetically from [3H]arachidonic acid (240 Ci/mmol, see Methods 
and Materials). This 3H ligand permitted the study of binding of LTB4 at nanomolar 
concentrations.  [14C]LTB4 of much  lower  specific  activity was  used  as  a  blocking 
ligand.  The  [3H]LTB4 and  [14C]LTB4 molecules behaved  identically  on TLC  and 
HPLC,  gave identical  ultraviolet  spectra,  and  gave nearly  identical  dose  response 
curves in an agarose chemokinetic assay (not shown) with peak potency at  1 nM. The 
chemokinetic  activity  of our  labeled  LTB4  agree  well  with  previously  published 
reports from other laboratories (12,  13, 21) and indicate that our radiolabeled ligand 
preparations have the expected level of biological activity. 
Binding of[aH]LTB4 to human PMN.  Fig.  2A shows typical time courses for the 
binding of [3H]LTB4 at 4°C and 37°C. At 4°C, total binding increased rapidly over 
the first  5 rain, increased more slowly over the next 40 rain, had leveled off by 60 rain 
(Fig.  2), and remained constant for up to 120 rain (not shown). Binding of [3H]LTB4 
at 37°C, however, showed a  very different time course. Total binding was maximal 
at  5  rain  and  decreased  thereafter.  This  decrease  in  the cell-associated counts was 
associated with the appearance of a  [aH]-labeled metabolite of LTB4 in the superna- 
tant as discussed below. To minimize this effect, all experiments were carried out at 
4°C. Total binding was linear with cell concentration as shown in  (Fig.  2B).  A cell 
concentration of 1.5  ×  107 cells/ml was routinely used, which bound 5-10% of the 
total ligand (range 3-13% for eight experiments). 
Recovery of cells  through the gradient was measured by protein determination of 
the  pellet  and  was  linear  with  cell  concentration  (not  shown).  Although  LTB4  is 
known to cause agglutination and changes in cell  density and  volume (35,  36),  no 
changes  in  the  recovery of cells  through  the  gradient  occurred under  any  of the 
conditions tested.  Recovery of lymphocytes was identical to that of PMN as deter- 
mined by cell surface iodination studies (data not shown). 
Blocking of [ 3  H] L TB4 Binding to PMN by [ t4 C] L TB~  The effect of various concen- 
trations of [X4C]LTB4 on the binding of cells incubated with 8 nM [3H]LTB4 is shown 
in Fig. 3. Inhibition of [3H]LTB4 binding by [14C]LTB4 demonstrates competition for 
a saturable number of sites  and represents specific binding. From Fig. 3 it is evident 
that  [aH]LTB4 binding changed very little  as  the  concentration of [14C]LTB4 was 
increased from 1 ×  10  -6 M  to 3 ×  10  -6 M. Maximal inhibition ranged from 65 to 80% 
in this concentration range. Based on the assumption of reversibility (see below), the 
50% inhibitory concentration (ICs0) of the blocking gives an apparent affinity constant 
(KD) of 2 ×  10  -7 M  for the specific binding sites.  From the difference between total R,  A,  KREISLE AND CHARLES W.  PARKER  633 
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FIG. 3.  The effect of varying concentrations of [14C]LTB4 on the binding of [aH]LTB4. 2 X  10  7 
cells/ml  were incubated  with  6  nM  [SH]LTB4 in  the  presence of varying  concentrations  of 
14  0  14  3  [  C]LTB, for 45 rain at 4 C. In the absence of{' C]LTB4, 350 -t- 15 cpm of[ H]LTB4 were bound. 
CPM determinations were corrected for 14C ~  aH crossover. Each data poi~nt represents the mean 
:1: SD of triplicate determinations. 
and  nonspecific binding at  I  ×  10  -s M  [14C]LTB4, the minimal  number of specific 
binding sites per cell is 3.86 ×  105 (4"0.72 SEM, n =  6). Because the amounts of LTB4 
available  were  limited,  repeated  experiments  at  higher  LTB4 concentrations  could 
not  be  performed,  and  the  presence  of additional  low  affinity  binding  sites  is  not 
excluded. 
Fig. 4 shows the binding of [3H]LTB4 as a  function of increasing concentration of 
free  LTB4.  Nonspecific binding,  as  determined  by the  binding of [3H]LTB4 in  the 
presence of 1 ×  10  -5 M  [a4C]LTB4, is linear over the concentration range tested and 
represents  2.5%  of the  free ligand concentration.  Specific binding is  determined  by 
subtracting  the nonspecific binding from the total binding and is  approximated  by 
the solid circles  in Fig.  4. Although the specific binding curve is  not quantitatively 
determined by these points, it can be seen that the curve is approaching saturation at 
concentrations above 150 nM. 
Ability of ['4C]LTB4 to Block the Binding of [3H]FMLP to PMN.  Binding by [X4C]- 
LTB4 at  4°C was also studied  for its  ability to block a  second chemokinetic  agent, 
FMLP. Excess LTB4 (1 pM)  at a  concentration of [14C]LTB4 that reduces  [aH]LTB4 
binding to PMN by 70-80% does not affect [aH]FMLP binding to these cells at any 
point  in  the  time  course.  At  37°C,  blocking  was  seen  only  at  10  pM  LTB4  and 
represented  <35% of the total FMLP binding  (data not shown, n =  3 experiments). 
These data suggest that LTB4 and FMLP react with different receptors and that most 
of the self inhibition  by LTB4 does not  involve nonspecific cellular  aggregation or 
surface membrane changes. 
Specificity of [aH]LTB4 Binding to PMN.  Preliminary experiments  examining the 
ability  of different  lipids  to  block  the  binding  of LTB4  to  PMN  demonstrated  a 
relative  inhibitory  capacity of [x4C]LTB4 >  5-HETE  >  arachidonic  acid  =  12-OH 
stearic  acid  (data  not  shown).  LTB4  was  at  least  3-10-fold  more  effective  than  5- 634  LEUKOTRIENE  B4  RECEPTOR 
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F~o.  4.  Total and nonspecific binding of [aH]LTB4  to PMN. Cells were incubated at a concentra~ 
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FEc.  5.  Ability of the 5,12-diHETE stereoisomers, 6-trans-LTB4, and 12-epi-6-trans-LTB4, to block 
[SH]LTB4 binding to PMN. Cells were incubated at a concentration of 3 ×  107 cells/ml for 25 rain 
at 4°C with 6 nM [aH]LTB4  and varying concentrations of [14C]LTB4 ([-]), 6-trans-LTB4 (C)), and 
12-epi-6-trans-LTB4 (0).  Aliquots containing  3  ×  106  cells  were processed as  in  Fig.  2.  Specific 
binding was determined as the difference between binding in the absence of any blocking agent and 
the  [aH]LTB4  binding in  the  presence of 10  -5  M  ['4C]LTB4.  The binding at  any given  blocker 
concentration  was  adjusted  for  nonspecific  binding,  and  the  percent  of control  binding  was 
calculated. Each point represents mean +- SD for triplicate determinations. 
HETE in blocking the binding of the [3H] ligand. Further specificity of the system is 
demonstrated by a comparison of the ability of the stereoisomers 6-trans-LTB4 and 12- 
epi-6-trans-LTB4  to block the binding of [3H]LTB4 (Fig. 5).  The inhibition curves for 
6-trans-LTB4 and 12-epi-6-trans-LTB4 were shifted to the right (less effective inhibition) 
as compared with the curve for [14C]LTB4. This represents an approximate threefold 
increase  in  the  concentration  of 6-trans-LTB4  and  12-epi-6-trans-LTB4  required  to R,  A.  KREISLE AND  CHARLES W.  PARKER 
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Fro. 6.  Reversibility of [SH]LTB4 binding to human PMN. In panel A, PMN were incubated at 
a concentration of t.4 X l0  ~ cells/ml with 3.6 nM [SH]LTB4 for 30 min at 4°C in a total volume of 
400/~1. At 30 min, 50 #1 of buffer (I-l) or [14C]LTB4 (A) (final concentration of 700 nM) was added. 
Aliquots were removed at 0, 15, 30, and 45 min after addition of the buffer or ligand and compared 
with a simultaneous time control (C)) in which 50 #1 of buffer was added at the beginning of the 
incubation. In panel B, PMN at a concentration of 3 ×  107 cells/ml were incubated with 4 nM 
[aH]LTB4 in the presence (A, &) or absence ((3, Q) of 1 #M" [14C]LTB4 in a final volume of 1 ml for 
45 rain at 4°C. At the end of this incubation, the cells were pelleted  at 2,000 rpm for 2 min, the 
supernatant was removed, and the pellets were resuspended at twice the incubation  volume in either 
buffer alone (O, &) or the original snpernatant (C), A), and aliquots were removed at the indicated 
time after resuspension. Aliquots were processed as in Fig. 4 and each point represents mean +  SD 
of triplicate samples. 
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reduce  [aH]LTB4  binding by  25-75%  as  compared  with  [14C]LTB4.  The  maximal 
amount  of blocking  seen  by  all  three  isomers  is  the  same.  Although  LTB4  was 
distinguishable  from  both  6-trans-LTB4  and  12-epi-6-trans-LTB4  as  an  inhibitor of 
[3H]LTB4  binding, 6-trans-LTB4  and  12-epi-6-trans-LTB4  were  quite  comparable  to 
one another  in this regard.  We  also looked at  the ability of the  5S,12S-DHETE  to 
block the binding of [3H]LTB4. At  1 ×  10  -6 M, this isomer was able to block nearly 
as well, but certainly not better, than the LTB4 itself (R. A. Kreisle and C. W. Parker, 
manuscript in preparation). 
Reversibility of[ZH]LTB4 binding to PMN.  To examine the reversibility of [aH]LTBa 
binding, cells were  incubated for  30  min at  4°C  with  3.6  nM  [3H]LTB4,  at  which 
time 700 nM  [14C]LTB4 or buffer was added in a  small volume (Fig. 6A). Little or no 
reversibility was  demonstrated on addition of 200-fold excess  of [14C]LTB4 over the 
original total  LTB4 present, although  further uptake of [3H]LTB4 was  inhibited. In 
the experiment shown in Figure 6 B, cells were incubated with 4  nM  [3H]LTB4 with 
or  without  1 #M  [14C]LTB4  for  45  rain  at  4°C.  The  cells  were  then  pelleted  and 
resuspended in twice the original volume of supernatant  (containing label) or buffer 
alone.  Again,  no reversibility was  seen  over  a  period  of 90  rain.  Thus,  neither the 636  LEUKOTRIENE B4  RECEPTOR 
addition  of excess  [a4C]LTB4  nor  resuspension  in  ligand-free  medium  convincingly 
promoted the release of cell-bound counts. The lack of evidence for dissociation could 
be due to covalent binding of LTB4,  its internalization  and  unavailability to surface 
ligand, or a  low kinetic constant  for dissociation of a  reversible binding site at the cell 
membrane.  The  first  possibility is unlikely,  since neither we  (W.  Stenson  and  C.  W. 
Parker,  unpublished  data)  nor  others  (37)  have  been  able  to  demonstrate  covalent 
binding  of LTB4  to  cellular lipids,  in  marked  contrast  to  the  monohydroxy-eicosa- 
tetraenoic acids  (1,  37).  Moreover, when  LTB4 is bound  to cells at  4°C  and  the cells 
are then washed  and  incubated  further at  37°C,  the radiolabel  is rapidly eluted into 
the medium,  so there is no doubt  that  association  with cells is reversible  (75%  by 45 
min, data not shown). 
Binding of[aH]LTB4 to Lymphocytes.  In addition  to PMN,  we examined  the ability 
of human  peripheral  blood lymphocytes to specifically bind  [3H]LTB4. The ability of 
2 ×  106 lymphocytes to bind [3H]LTB4 was compared with an equal number  of PMN 
in  the  presence  and  absence  of  1 /~M  [a4C]LTB4.  Both  the  total  number  of counts 
bound  (156 +  36 vs.  73 ±  8)  and  the percentage of blocking seen with the [14C]LTB4 
(55% vs. 37%)  was greater with the neutrophils  than with the lymphocytes.  The time 
course of binding and recovery of cells through  the 30% Ficoll-Hypaque gradient was 
similar for the two cell populations  (data not shown). 
Metabolism of[~H]LTB4 on Incubation with PMN.  In view of the striking loss of cell- 
associated  counts  on  incubation  of PMN  with  [aH]LTB4  at  37°C  (Fig.  2)  and  the 
TABLE  II 
Metabolism of [a H]5,12 diHETE in Human Neutrophils * 
Percent of recovered counts:~ 
Band[[  rf 
4°C  37°C 
10 rain  40 rain  10 min  60 min  No cell  No cell 
(control)  (142,780  (101,925  (control)  (67,660  (73,555 
( 139,680  cpm)  cpm)  (44,350  cpm)  cpm) 
cpm)  SN¶  Pellet  SN  Pellet  cpm)  SN  Pellet  SN  Pellet 
1  0.02  0.03  0.5  1.3  3.4  2.0  3.5  4.2  9.5  3.7  13.4  1.0 
2  0.05-0.07  --  1.1  7.7  1.3  8.6  3.7  23.0  42.0  63.0  3.6 
3  0.13-0.15  .....  5.4  3.2  2.2  5.9  <1 
4  0.16-0.19  87.8  47.0  20.5  39.8  26.5  69.7  12.5  3.8  11.8  <1 
5  0.19-0.24  8.1  10.9  3.4  7.3  4.3  ..... 
6/7  0.38  0.45  2.0  --  --  3.1  --  17.0  .... 
Total  98.4  60.3  35  53.5  42.9  i00.0  48.2  51.7  94.1  4.6 
* 2.5 ×  107 cells were incubated with 20 nm [aH]LTB4 at either 4°C or 37°C. After incubation for the 
indicated  time  the  supernatants  and  pellets  were separated  and  extracted  with  ethanol/ether.  The 
extracts  were then analyzed by TLC (Silica get G-coated plates;  benzene/diethyl ether/ethanol/acetic 
acid, 50:40:2.0:0.2, vol/vol/vol/vol). 
:[: The figures in the table represent  the % of the original CPM recovered  for that incubation (total pellet 
plus supernatant). The overall recovery of radioactivity was -~90%. 
§ Total amount of counts recovered  (pellets + supernatant)  for an aliquot of cells taken at the given time 
(mean of two). 
[[ Bands were visualized by autoradiography and identified by comparison with LTB4 standard. Band 4 co- 
migrated with [3H]LTB4. 
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apparent  lack  of reversibility  at  4°C  but  not  at  37°C,  we  looked  to  see  if any 
differences existed in the cell-bound vs. free ligand at both temperatures. Briefly, we 
incubated the PMN with 20 nM [3H]LTB4 for 10 or 40 min at 4°C  (10 or 60 min at 
37°C).  The incubation  mixtures were centrifuged, and the supernatants  and pellets 
were extracted separately with ethanol/ether (7).  These extracts were then subjected 
to TLC as described in  Materials  and Methods.  A  total of seven major and minor 
bands appeared on radioautography of the TLC plates (Table II). A  no-cell control 
was run for comparison in which [SH]LTB4 was incubated in buffer at each temper- 
ature and extracted in the same way as the cell suspensions. 
Band  4  represents unaltered  [SH]LTB4 and  is the major form of the aH label at 
both temperatures on incubation in the absence of cells. At 4°C, the total amount of 
unchanged ligand recovered in the supernatant  and pellet together was 67 and 66% 
for 10 and 40 min, respectively. At both of these times about 30% of the remaining 
LTB4 was cell bound.  Nearly 25% of the cell-bound ligand is in the form of band 2. 
Band  2  is  probably  the  20-hydroxy  derivative  of LTB4  (5,12,20-trihydroxy-ETE) 
which  has recently been characterized  by Hansson  et  al.  (38)  in  human  leukocyte 
preparations. 
After only 10 rain at 37°C, almost 50% of the original counts are cell-bound and 
>80%  of these are in band  2,  but  7-8% are in LTB,.  By 60 min, <7% of the total 
counts are associated with the pellet. This agrees well with the loss of cell-associated 
counts in  the time course study of binding at  37°C  (Fig.  2).  After 60 min at  37°C 
there is no longer any cell-associated LTB4, providing further evidence for reversibility 
of binding at  this temperature.  In addition,  at  10  min  23%  of the total counts are 
present in the supernatant  as band 2. At 60 rain, this fraction has increased to 63% 
and corresponds quantitatively to the loss of band-2 counts associated with the cell 
pellet. Band 5 is a doublet and corresponds to the stereoisomers, 6-trans-LTB4 and 12- 
epi-6-trans-LTB4, which also occur in small quantities in the cell-free control (but not 
in the LTB, standard, not shown). Bands  1, 3, 6, and 7 are as of yet unidentified but 
are quantitatively minor in any case. 
Discussion 
Several  lines  of evidence  support  a  role  for arachidonic  acid  metabolites  in  the 
chemotaxis, aggregation, and degranulation of PMN (1, 8-18, 35-36, 39, 40). In this 
study we have demonstrated the ability of PMN to specifically bind  [ZH]LTB4, the 
most  potent  of the  arachidonic  acid  metabolites  in  inducing  PMN  activity:  (a) 
Maximal  or near  maximal  blocking of [3H]LTB4  binding  by  [14C]LTB4  occurs  at 
concentrations of 1/~M or greater and represents 65-80% of the total binding.  Thus, 
at low molar concentrations of [3H]LTBa nonspecific binding may represent as little 
as 20% of the bound ligand. Reversibility of binding is readily demonstrable at 37°C 
although not at 4°C.  (b)  Due to the slow dissociation rate seen at 4°C, a  Scatchard 
plot of these data is inappropriate for determining receptor affinity (K9) or number 
of sites (41). A minimum number of specific binding sites, however, can be determined 
from maximal amounts of inhibition  seen at concentrations  of 1 pM  [a4C]LTB4  or 
greater  (3.9  X  105  specific  sites  per  cell,  n  =  6).  In  addition,  affinity  can  be 
approximated by the concentration of IC5o of [14C]LTB4 which blocks half the specific 
sites (Ko =  1-2 ×  10  -7 M  for Figs. 3 and 5). The specific binding shown in Fig. 4 is 
consistent with these values, although saturation of binding is not shown. Because the 638  LEUKOTRIENE B4  RECEPTOR 
maximal LTB4 concentration  we were able to use in our binding studies was  10  × 
10  -6 M, the presence of additional binding sites of lower affinity is not excluded.  (c) 
Competition for [3H]LTB4 binding was greater with [14C]LTB, than with the stereo- 
isomers 6-trans-LTB4 and 12-epi-6-trans-LTB4, 5-HETE, arachidonic acid itself, or 12- 
hydroxystearate,  another  hydroxylated  long  chain  fatty  acid.  The  discrimination 
between  LTB4 and its two 6-trans  isomers indicates that  there is stereospecificity of 
binding. The relative activities of the three 5,12-diHETE in inhibiting LTB, binding 
is consistent with their relative potencies in inducing chemokinesis (21). The binding 
of LTB4 was not  due to "contamination  s' by the  5S,12S-6trans,8-cis,lO-trans,14-cis,  - 
ETE isomer, 5S,12S-DHETE  (30,  42)  which  is minimally represented  in our LTB4 
preparations due to our use of TLC system, which largely separates this isomer from 
LTB4 in our routine preparative procedure. Moreover, if anything, this isomer blocks 
[3H]LTB4 binding  less well  than  LTB4.  (d)  At  equivalent  cell concentrations  both 
total and specific binding were greater in PMN than lymphocytes. Both the molecular 
and cellular specificities of LTB4 binding demonstrated  in  this study are consistent 
with the existence of a specific receptor for LTB4 on PMN. 
Precise quantitation  of LTB, binding with increasing ligand  concentrations  may 
be complicated  by the  ability  of this  agent  to  aggregate  PMN  and  increase  their 
adherence  to  foreign  surfaces.  Both  of  these  properties  increase  with  increasing 
concentrations of LTB4, incubation time, and incubation temperature. Quantitation 
of protein in the cell pellets, however, showed no loss of cell recovery under any of the 
conditions tested. Moreover, the ability of PMN to bind [3H]FMLP was not affected 
by [a4C]LTB4 under conditions which maximally inhibited  [3H]LTB4 binding. Thus, 
little if any of the inhibition seen by blocking concentrations of [14C]LTB4  could be 
attributed to these effects. 
The binding of our [3H]LTB4 appeared to be irreversible at 4°C, but not at 37°C. 
The  most  likely explanation  is a  very slow  off rate  (kinetic  dissociation  constant). 
While one could speculate as to whether the LTB4 is sequestered in some manner (by 
incorporation into phospholipids),  or internalization  in endocytotic vesicles, studies 
with  LTB4  have  failed  to  demonstrate  any  esterification  into  phospholipids  or 
triglycerides  in  neutrophils  (W.  Stenson  and  C.  W.  Parker,  unpublished  data)  or 
monocytes (37).  The availability of LTB4 for metabolism and transport back out of 
the  cell  at  37°C  strongly argues  against  any irreversible sequestration  into  a  non- 
reactive lipid pool. Based on the data at 37°C alone, it might be argued that LTB4 is 
stimulating endocytosis, facillitating its own uptake and metabolism by cells.  How- 
ever, the blocking of [3H]LTB4 binding by [14C]LTB4 is hard to explain on this basis 
unless the endocytosis itself is initiated through a specific receptor. The stereospecific 
uptake of LTB4  at  4°C,  where  increased  endocytosis  in  response  to  an  exogenous 
stimulus would not be expected, would also appear to require a specific receptor. 
The physiological relevance of this specific LTB, binding is unknown.  However, 
the  relative abilities  of [a4C]LTB4,  6-trans-LTB,,  12-epi-6-trans-LTB4,  5-HETE,  and 
arachidonic  acid  to  inhibit  the  binding  of LTB4  do  correspond  to  their  relative 
potencies in inducing chemotaxis. Further attempts to correlate function with specific 
binding of LTB4 will require that the cellular constituents involved in LTB4 binding 
be characterized both in terms of location and molecular structure. 
Summary 
In  this  paper  we  have  described  the  binding  of  nanomoler  concentrations  of 
[aH]leukotriene B4  (LTB4)  to human polymorphonuclear leukocytes. Because up to R.  A.  KREISLE AND CHARLES W.  PARKER  639 
80% of the total [3H]LTB4 binding was blocked by excess (>I00 times)  [14C]LTB4, the 
majority of binding is specific. Stereospecificity of the LTB4 binding is demonstrated 
by the diminished relative abilities  of the 6-trans-and  12-epi-6-trans-  isomers of LTB4 
to block [3H]LTB4 binding. With these two isomers 3-10-fold higher than  [14C]LTB4 
concentrations  were  needed  for  equivalent  inhibition  of  [3H]LTB4  binding.  This 
difference is quantitatively  less dramatic  than  the differences between  these isomers 
in many in vitro functional assays such as chemokinesis, chemotaxis, and degranula- 
tion. Binding of [3H]FMLP is not blocked at >100-fold excess of LTB4. The binding 
of [3H]LTB4 to cells  appears  to be essentially  irreversible  at  4°C,  but  not  at  37°C 
where initially bound LTB4 is rapidly converted to metabolites which then enter the 
medium. These results suggest the presence of a saturable, stereospecific site for LTB4 
on  PMN.  The  association  of LTB4  binding  and  the  initiation  of pharmacological 
responses to LTB4 will require further studies. 
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